AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DDAVP spray at doses ranging from 20 to 40 mcg/day
Trial: 8682086
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus IFN
Trial: 8682086
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus thymomodulin
Trial: 8682086
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus IFN and thymomodulin
Trial: 2351902
Drug: Conventional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional infusion
Trial: 31973934
Drug: Coolant spray
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Trial: 12188410
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline spray (placebo)
Trial: 31973934
Drug: Coolant spray
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coolant spray
Trial: 20958851
Drug: Group Drug
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Drug Counseling (GDC)
Trial: 22465116
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP)
Trial: 17963466
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol and ketamine
Trial: 17963466
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of ketamine added to propofol
Trial: 16131580
Drug: L-T4 (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T4 (titrated to maintain low TSH)
Trial: 16131580
Drug: L-T4 (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T4 (titrated to restore euthyroidism)
Trial: 11853247
Drug: Resin-sealant (Concise)
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin-sealant (Concise) with acid etch and tooth preparation
Trial: 11853247
Drug: Compomer restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer restorative material (F2000) with acid etch, bonding agent, and tooth preparation
Trial: 11853247
Drug: Compomer restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer restorative material (F2000) with bonding agent and no tooth preparation
Trial: 11853247
Drug: Compomer restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer restorative material (F2000) with bonding agent and tooth preparation
Trial: 11853247
Drug: Compomer restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer restorative material (F2000) with bonding agent and without enameloplasty
Trial: 11853247
Drug: Compomer with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer with acid etching and bonding agent
Trial: 8950882
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg per day
Trial: 7039533
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (30 to 60 mg orally for six days before operation)
Trial: 28835059
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1) + flurbiprofen axetil 200 mg)
Trial: 28835059
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (hydromorphone hydrochloride 2 μg·kg(‐1)·h(‐1))
Trial: 28835059
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1))
Trial: 24770960
Drug: Alcohol SPN
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol SPN (1 ml of absolute alcohol injected under CT guidance)
Trial: 7587855
Drug: AC137 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AC137 infusion (50 micrograms/h) during a standardized Sustacal meal (350 kcal) challenge.
Trial: 7587855
Drug: AC137 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AC137 infusion (steady-state concentrations of 234 +/- 16 pmol/l) during an intravenous glucose load (300 mg/kg).
Trial: 2210097
Drug: 80 mM
RxNorm normalized name: Koromex Coil Diaphragm 80 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mM glucose-sodium chloride solution
Trial: 2210097
Drug: Ileal glucose-stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal glucose-stimulated water absorption
Trial: 2210097
Drug: Jejunal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jejunal glucose absorption
Trial: 2210097
Drug: Ileal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal glucose absorption
Trial: 26547414
Drug: LF-0.6 (formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF-0.6 (formula with 0.6 g/L bLf)
Trial: 26547414
Drug: LF-1.0 (formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF-1.0 (formula with 1.0 g/L bLf)
Trial: 19276858
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of 19‐norandrostenedione
Trial: 15358988
Drug: Reboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 4 mg/day
Trial: 9013010
Drug: Lytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lytic therapy followed by heparin and warfarin (group 2)
Trial: 9013010
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (heparin and warfarin) (group 1)
Trial: 1334103
Drug: Conservative surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative surgery and radiation therapy
Trial: 28716351
Drug: Home-based curative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based curative health services provided by trained lady health workers (LHWs) including neonatal bag and mask resuscitation and oral amoxicillin for suspected infections.
Trial: 17309383
Drug: Agaricus blazei
RxNorm normalized name: AGARICUS BLAZEI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agaricus blazei Murill (ABM) extract 1500 mg daily for 12 weeks
Trial: 9556464
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg of aspirin every other day
Trial: 9556464
Drug: Self-selected aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected aspirin use after 1988
Trial: 3228680
Drug: Caffeine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (7 mg.kg‐1)
Trial: 18220486
Drug: pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 45 mg/day
Trial: 26311750
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of DFZ
Trial: 26311750
Drug: Daily PRED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PRED
Trial: 26311750
Drug: Daily DFZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily DFZ
Trial: 23146816
Drug: Tariquidar (TQD)
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (TQD) at 4 mg/kg
Trial: 23146816
Drug: Tariquidar (TQD)
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (TQD) at 6 mg/kg
Trial: 23146816
Drug: Tariquidar (TQD)
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (TQD) at 8 mg/kg
Trial: 22011689
Drug: Tocilizumab 10
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 10 mg/kg
Trial: 22011689
Drug: Tocilizumab 20
RxNorm normalized name: tocilizumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 20 mg/kg
Trial: 17021768
Drug: Efalizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (1 mg/kg once weekly)
Trial: 17021768
Drug: Efalizumab (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (extended treatment phase)
Trial: 17021768
Drug: Efalizumab (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (long-term treatment phase)
Trial: 14735295
Drug: quetiapine 25
RxNorm normalized name: quetiapine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine 25 mg
Trial: 14735295
Drug: quetiapine 100
RxNorm normalized name: quetiapine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine 100 mg
Trial: 11103798
Drug: ONYX-015 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONYX-015 (1 x 10^10 pfu via intratumoral injection for 5 days during week 1 of each 3-week cycle)
Trial: 11103798
Drug: ONYX-015 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONYX-015 (1 x 10^10 pfu twice a day for 10 days during weeks 1 and 2 of each 3-week cycle)
Trial: 9197929
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) administration at 4000 micrograms per day from 4 days before to 4 days after chemotherapy in group A.
Trial: 9197929
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) administration in group A.
Trial: 9197929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Se administration in first cycle, Se in second cycle).
Trial: 2991832
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen for 25 days each month
Trial: 2991832
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of depo‐medroxyprogesterone acetate intramuscularly every three months
Trial: 18812733
Drug: 3% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% albumin solution (L group, n = 68)
Trial: 16815748
Drug: Pramipexole 0.125
RxNorm normalized name: pramipexole 0.125 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.125 mg
Trial: 16815748
Drug: Pramipexole 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.50 mg
Trial: 10972371
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice-weekly subcutaneous injections)
Trial: 9117012
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg for 2 weeks followed by 10 mg for 4 weeks)
Trial: 9032569
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment groups
Trial: 10071548
Drug: Alfuzosin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (12 months treatment)
Trial: 10071548
Drug: Alfuzosin (12-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (12-18 months treatment)
Trial: 3728935
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids (2 litres)
Trial: 31917122
Drug: SOX (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2 of S-1 on days 1-14, every 21 days, 8 cycles)
Trial: 31917122
Drug: UFT/LV (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 cycles)
Trial: 27842269
Drug: Intensive Language‐Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Language‐Action Therapy (ILAT)
Trial: 27842269
Drug: Naming Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naming Therapy
Trial: 24200249
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (shavasana with soothing background music) daily for 1 hour for 6 weeks
Trial: 23357775
Drug: Tigecycline 100
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 100 mg (150 mg followed by 75 mg every 12 h)
Trial: 23357775
Drug: Tigecycline 75
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 75 mg (200 mg followed by 100 mg every 12 h)
Trial: 23357775
Drug: Imipenem/cilastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1 g every 8 h)
Trial: 14974909
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen (Premarin 1.25 mg) + Norethisterone (2.5 mg)
Trial: 14974909
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + MPA (10 mg)
Trial: 14974909
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Norethisterone (2.5 mg)
Trial: 14974909
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg)
Trial: 14974909
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + CA (5 mg)
Trial: 14974909
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Dydrogesterone (20 mg)
Trial: 14974909
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen (Premarin 1.25 mg) + Progestogens (various types)
Trial: 14974909
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Progestogens (various types)
Trial: 14974909
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg) and Norethisterone (2.5 mg)
Trial: 12574184
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/d
Trial: 12458987
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (alendronate and estrogen)
Trial: 10697060
Drug: Estrogen 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen 0.625 mg/d
Trial: 7738622
Drug: 5‐FU 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 with DP 75 mg orally three times daily on days 1 to 5
Trial: 7738622
Drug: 5‐FU 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 without DP
Trial: 1914056
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% bupivacaine with epinephrine 5 micrograms.ml‐1 (bupivacaine group, n = 10)
Trial: 1914056
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml preservative-free saline (placebo group, n = 10)
Trial: 7267679
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg LM 5008
Trial: 14550686
Drug: IV heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV heroin maintenance treatment
Trial: 14550686
Drug: IV methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV methadone maintenance treatment
Trial: 8669677
Drug: 5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% hyperbaric lidocaine with epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Trial: 8669677
Drug: 2% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% isobaric lidocaine without epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Trial: 8669677
Drug: 0.75% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% hyperbaric bupivacaine without epinephrine (7.5 mg for arthroscopy or 9.0 mg for hernia repair)
Trial: 3897560
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg Oltipraz (single dose)
Trial: 3897560
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg Oltipraz (split dose)
Trial: 27531573
Drug: Tramadol hydrochloride/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol hydrochloride/acetaminophen combination (TRAM/APAP)
Trial: 3157894
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (NSAID)
Trial: 15688279
Drug: rgp120 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp120 vaccine
Trial: 8991490
Drug: Dilacor XR
RxNorm normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilacor XR (180 mg d‐1)
Trial: 8991490
Drug: Dilacor XR
RxNorm normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilacor XR (540 mg d‐1)
Trial: 1318364
Drug: Foscarnet (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (200 mg/kg continuous infusion prior to 1988 or 60 mg/kg t.i.d. or 90 mg/kg b.i.d. intermittent infusion with saline hyperhydration)
Trial: 6147838
Drug: lormetazepam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lormetazepam (1.5 mg)
Trial: 6353523
Drug: flurazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flurazepam (30 mg)
Trial: 11104841
Drug: temazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temazepam (30 mg)
Trial: 6147838
Drug: active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active drug conditions (lormetazepam, flurazepam, temazepam)
Trial: 6147838
Drug: active drugs
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active drugs
Trial: 29743078
Drug: MIV‐711 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV‐711 (single oral doses from 20 to 600 mg in humans; 3‐30 µmol/kg in monkeys)
Trial: 29743078
Drug: MIV‐711 (repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV‐711 (repeat oral dosing)
Trial: 21239190
Drug: AS195 (red-vine-leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS195 (red-vine-leaf extract) 720 mg per day for 12 weeks
Trial: 12728086
Drug: 3-component acellular
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-component acellular pertussis vaccine administered at birth (group 1)
Trial: 12728086
Drug: 3-component acellular
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-component acellular pertussis vaccine administered at 3, 5, and 11 months (group 2)
Trial: 10992828
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen 1 mg kg‐1
Trial: 10992828
Drug: Oral ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoprofen 1 mg kg‐1
Trial: 10992828
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and i.v. placebo
Trial: 31399460
Drug: Daily observed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily observed treatment
Trial: 31399460
Drug: Treatment dispensed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment dispensed every 2 weeks
Trial: 31399460
Drug: Treatment dispensed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment dispensed every 2 weeks with adherence psychological intervention
Trial: 24418726
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg intravenously, acute)
Trial: 24418726
Drug: Acetazolamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (2 g orally, prolonged)